236 related articles for article (PubMed ID: 3909387)
1. [Transplantation of allogeneic bone marrow treated in vitro with Campath-1 monoclonal antibody].
Chapuis B; Helg C; Maurice P; Wyss M; Pipard G; Irlé C; Jeannet M
Schweiz Med Wochenschr; 1985 Oct; 115(43):1521-2. PubMed ID: 3909387
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial depleting T lymphocytes from donor marrow for matched and mismatched allogeneic bone marrow transplants.
Trigg ME; Billing R; Sondel PM; Exten R; Hong R; Bozdech MJ; Horowitz SD; Finlay JL; Moen R; Longo W
Cancer Treat Rep; 1985 Apr; 69(4):377-86. PubMed ID: 3888387
[TBL] [Abstract][Full Text] [Related]
3. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
[TBL] [Abstract][Full Text] [Related]
4. Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.
Cobbold SP; Hale G; Clark MR; Waldmann H
Prog Clin Biol Res; 1990; 333():139-51; discussion 152-4. PubMed ID: 2308978
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
6. Unrelated donor bone marrow transplantation for children with severe aplastic anemia: minimal GVHD and durable engraftment with partial T cell depletion.
Bunin N; Aplenc R; Iannone R; Leahey A; Grupp S; Monos D; Pierson G
Bone Marrow Transplant; 2005 Feb; 35(4):369-73. PubMed ID: 15640818
[TBL] [Abstract][Full Text] [Related]
7. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
8. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
[TBL] [Abstract][Full Text] [Related]
9. [Quantitative determination of human bone marrow T cells following in vitro depletion by Campath-1 monoclonal antibody].
Irlé C; Kaestli M; Chapuis B; Jeannet M
Schweiz Med Wochenschr; 1985 Oct; 115(43):1517-8. PubMed ID: 3909385
[TBL] [Abstract][Full Text] [Related]
10. [Prevention of graft versus host disease by in vitro depletion of T lymphocytes with monoclonal antibodies (Campath-1) in patients undergoing bone marrow transplantation].
Iriondo A; Richard C; Hermosa V; Conde E; Garijo J; Cuadrado MA; Bello C; Muruzábal MJ; Pérez-Encinas M; Zubizarreta A
Med Clin (Barc); 1988 Oct; 91(13):488-92. PubMed ID: 3067007
[No Abstract] [Full Text] [Related]
11. Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
Hale G; Waldmann H
Bone Marrow Transplant; 1994 May; 13(5):597-611. PubMed ID: 8054913
[TBL] [Abstract][Full Text] [Related]
12. T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease.
Jacobs P; Wood L; Fullard L; Waldmann H; Hale G
Bone Marrow Transplant; 1994 Jun; 13(6):763-9. PubMed ID: 7920312
[TBL] [Abstract][Full Text] [Related]
13. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
14. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
Slavin S; Or R; Naparstek E; Weiss L; Mumcuoglu M; Weshler Z; Brautbar H; Cividalli G; Glikson M; Hale G
Transplant Proc; 1987 Feb; 19(1 Pt 3):2614-5. PubMed ID: 3274569
[No Abstract] [Full Text] [Related]
16. Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Naparstek E; Delukina M; Or R; Nagler A; Kapelushnik J; Varadi G; Strauss N; Cividalli G; Aker M; Brautbar C; Waldmann H; Hale G; Slavin S
Exp Hematol; 1999 Jul; 27(7):1210-8. PubMed ID: 10390197
[TBL] [Abstract][Full Text] [Related]
17. T-cell depletion with the monoclonal antibody Campath 1 to prevent graft-versus-host disease in ten high-risk adult patients.
Bandini G; Ricci P; Gobbi M; Tazzari PL; Motta MR; Guardigli C; Rizzi S; Baccarani M; Tura S
Haematologica; 1986; 71(4):307-11. PubMed ID: 3096824
[No Abstract] [Full Text] [Related]
18. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
[TBL] [Abstract][Full Text] [Related]
19. [Transplantation of allogeneic bone marrow treated in vitro with Campath-1 monoclonal antibody].
Chapuis B; Maurice P; Helg C; Wyss M; Jeannet M; Irlé C; Pipard G
Schweiz Med Wochenschr; 1986 Oct; 116(43):1475-6. PubMed ID: 3538379
[TBL] [Abstract][Full Text] [Related]
20. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
